Spots Global Cancer Trial Database for mln8237
Every month we try and update this database with for mln8237 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | NCT02812056 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Alisertib TAK-228 | 18 Years - | M.D. Anderson Cancer Center | |
| Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies | NCT01677559 | Adenocarcinoma Pancreatic Neop... | MLN8237 nab-Paclitaxel | 18 Years - | Washington University School of Medicine | |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01812005 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | alisertib rituximab laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer | NCT01799278 | Small Cell Pros... Neuroendocrine ... Prostate Adenoc... | MLN8237 | 18 Years - | Weill Medical College of Cornell University | |
| MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | NCT02444884 | Unspecified Chi... Neuroblastoma | MLN8237 | 12 Months - 21 Years | Children's Oncology Group | |
| Study of MLN8237 in Combination With Irinotecan and Temozolomide | NCT01601535 | Neuroblastoma | MLN8237 Irinotecan Temozolomide | 12 Months - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | NCT01512758 | Advanced Solid ... Lymphomas | Alisertib | 18 Years - | Takeda | |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | NCT01512758 | Advanced Solid ... Lymphomas | Alisertib | 18 Years - | Takeda | |
| Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies | NCT01677559 | Adenocarcinoma Pancreatic Neop... | MLN8237 nab-Paclitaxel | 18 Years - | Washington University School of Medicine | |
| MLN8237 in Head and Neck Cancer | NCT01540682 | Head and Neck C... | MLN8237 Cetuximab Radiotherapy | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Study of MLN8237 in Combination With Irinotecan and Temozolomide | NCT01601535 | Neuroblastoma | MLN8237 Irinotecan Temozolomide | 12 Months - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| MLN8237 for a Subject With Adenocarcinoma of the Prostate | NCT03005262 | Prostate Cancer | MLN8237 | 18 Years - 100 Years | The University of Texas Health Science Center at San Antonio | |
| Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | NCT02293005 | Lung Cancer Mesothelioma | Alisertib | 18 Years - | M.D. Anderson Cancer Center | |
| Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | NCT01898078 | Advanced Solid ... Lymphoma | Alisertib | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
